Clinical Trials Browser

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

25 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Phase 2 Recruiting

50 enrolled

Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05592015 2026-02-10

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Phase 2 Recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Phase 2 Recruiting

60 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT06991101 2025-12-26

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

190 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Recruiting

124 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Recruiting

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07238712 2025-11-20

APTBCy

Phase 2 Recruiting

60 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT06128070 2025-10-31

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 2 Recruiting

40 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06397313 2025-09-23

POTAMI-61

Phase 2 Recruiting

230 enrolled

Myeloid

Neoplasm Metastasis, Primary Myelofibrosis

NCT05870475 2024-07-03

PV

Phase 2 Recruiting

94 enrolled

Myeloid

Polycythemia Vera

NCT06477549 2024-06-27

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Phase 2 Recruiting

220 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma